P540: RESULTS FROM A PHASE 1 CLINICAL STUDY OF THE ALL-ORAL REGIMEN OF CC-486 AND VENETOCLAX FOR RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (AML)

Benzer Materyaller

• P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
  Yazar:: Marina Konopleva, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-08-01)
• A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML
  Yazar:: A. Shastri, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-01-01)
• P540: RESULTS FROM A PHASE 1 CLINICAL STUDY OF THE ALL-ORAL REGIMEN OF CC-486 AND VENETOCLAX FOR RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
  Yazar:: Maria Amaya, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-08-01)
• P534: AZACITIDINE PLUS VENETOCLAX FOR THE TREATMENT OF RELAPSED AND FIRST-LINE AML PATIENTS
  Yazar:: S. Garciaz, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-06-01)
• P488: SAFETY AND EFFICACY OF VENETOCLAX PLUS “7 + 3” CHEMOTHERAPY IN NEWLY DIAGNOSED AML
  Yazar:: Ioannis Mantzaris, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-08-01)